FLT3 inhibitors: A story of the old and the new

Current Opinion in Hematology

Volumn 18, Issue 2, 2011, Pages 71-76

  Fathi, Amir ^a   Levis, Mark ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

acute myeloid leukemia; FLT3; internal tandem duplication; tyrosine kinase inhibitors

Indexed keywords

AC 220; ANTINEOPLASTIC AGENT; CD135 ANTIGEN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FMS LIKE TYROSINE KINASE 3 INHIBITOR; IDARUBICIN; KW 2449; LESTAURTINIB; MIDOSTAURIN; MITOXANTRONE; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SEMAXINIB; SORAFENIB; STEM CELL FACTOR; SUNITINIB; TANDUTINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CYTOTOXICITY; DRUG MEGADOSE; DRUG POTENCY; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY CARCINOMA; LEUKEMIA REMISSION; MUSCLE WEAKNESS; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE;

ACUTE DISEASE; BENZOTHIAZOLES; CELL SURVIVAL; CLINICAL TRIALS AS TOPIC; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID; MUTATION; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS;

EID: 79952043438     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283439a03     Document Type: Article

References (71)

1. Levis M, Small (Pubitemid 37185249)
2. Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010; 116:5089-5102.
3. Small D, Levenstein M, Kim E, et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34\+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA 1994; 91:459-463. (Pubitemid 24041421)
4. van der GeerP, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 1994; 10:251-337. (Pubitemid 24372822)
5. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10:1911-1918. (Pubitemid 27019637)
6. Kiyoi H, Towatari M, Yokota S, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998; 12:1333-1337. (Pubitemid 28442377)
7. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98:1752-1759.
8. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cyto-genetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 2001; 61:7233-7239. (Pubitemid 32946520)
9. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100:59-66. (Pubitemid 35177429)
10. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99:4326-4335. (Pubitemid 34627197)
11. Tse KF, Novelli E, Civin CI, etal. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia 2001; 15:1001-1010. (Pubitemid 32717268)
12. Levis M, Tse KF, Smith BD, etal. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 2001; 98:885-887.
13. Levis M, Allebach J, Tse KF, etal. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002; 99:3885-3891. (Pubitemid 35332023)
14. Kelly LM, Yu JC, Boulton CL, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 2002; 1:421-432. (Pubitemid 41039123)
15. Weisberg E, Boulton C, Kelly LM, etal. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002; 1:433-443. (Pubitemid 41039124)
16. Teller S, Kramer D, Bohmer SA, et al. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3. Leukemia 2002; 16:1528-1534.
17. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101:3597-3605. (Pubitemid 36857948)
18. Yee KW, O'Farrell AM, Smolich BD, etal. SU5416 and SU561 4 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood 2002; 100:2941-2949.
19. Gazit A, Yee K, Uecker A, et al. Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorg Med Chem 2003; 11:2007-2018. (Pubitemid 36379018)
20. Murata K, Kumagai H, Kawashima T, et al. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3). J Biol Chem 2003; 278:32892-32898. (Pubitemid 37055731)
21. Auclair D, Miller D, Yatsula V, et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 2007; 21:439-445.
22. Kiyoi H, Shiotsu Y, Ozeki K, et al. A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations. Clin Cancer Res 2007; 13:4575-4582. (Pubitemid 47219728)
23. Shiotsu Y, Kiyoi H, Ishikawa Y, etal. KW-2449, a novel multikinase inhibitor, • suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood 2009; 114:1607-1617.
24. Zarrinkar PP, Gunawardane RN, Cramer MD, etal. AC220 is a uniquely potent • and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009; 114:2984-2992.
25. Pratz KW, Cortes J, Roboz GJ, et al. A pharmacodynamic study of the FLT3 •• inhibitor KW-2449 yields insight into the basis for clinical response. Blood 2009; 113:3938-3946.
26. Smolich BD, Yuen HA, West KA, et al. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 2001; 97:1413-1421. (Pubitemid 32183767)
27. Mendel DB, Laird AD, Smolich BD, etal. Development of SU541 6, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an antiangiogenesis agent. Anticancer Drug Des 2000; 15:29-41. (Pubitemid 30364897)
28. Fiedler W, Mesters R, Tinnefeld H, etal. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003; 102:2763-2767. (Pubitemid 37248845)
29. Giles FJ, Stopeck AT, Silverman LR, etal. SU541 6, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003; 102:795-801. (Pubitemid 36917765)
30. O'Farrell AM, Yuen HA, Smolich B, etal. Effects of SU541 6, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk Res 2004; 28:679-689. (Pubitemid 38639735)
31. Loges S, Tinnefeld H, Metzner A, et al. Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU541 6. Leuk Lymphoma 2006; 47:2601-2609. (Pubitemid 44932651)
32. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124. (Pubitemid 46089672)
33. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368:1329-1338. (Pubitemid 44528723)
34. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26:3403-3410.
35. O'Farrell AM, Foran JM, Fiedler W, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003; 9:5465-5476. (Pubitemid 37499464)
36. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005; 105:986-993. (Pubitemid 40170865)
37. Camoratto AM, Jani JP, Angeles TS, et al. CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro and exhibits antitumor activity. Int J Cancer 1997; 72:673-679. (Pubitemid 27356171)
38. StrockCJ, ParkJI, Rosen M, etal. CEP-701 and CEP-751 inhibitconstitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res 2003; 63:5559-5563. (Pubitemid 37139878)
39. Hexner EO,Serdikoff C, Jan M, etal. Lestaurtinib (CEP701) isaJAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008; 111:5663-5671.
40. Marshall JL, Kindler H, Deeken J, etal. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs 2005; 23:31-37. (Pubitemid 39505949)
41. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004; 103:3669-3676. (Pubitemid 38596280)
42. Levis M, Brown P, Smith BD, et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 2006; 108:3477-3483.
43. Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006; 108:3262-3270.
44. Knapper S, Mills KI, Gilkes AF, etal. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood 2006; 108:3494-3503.
45. Levis M, Pham R, Smith BD, Small D. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood 2004; 104:1145-1150. (Pubitemid 39038036)
46. Brown P, Levis M, McIntyre E, etal. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rear-ranged ALL cells in a sequence-dependent manner. Leukemia 2006; 20:1368-1376. (Pubitemid 44084049)
47. Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for FLT3 mutant AML patients in first relapse [abstract]. Blood 2009; 114:788a.
48. Knapper S, Burnett A, Hills RK, et al. Lestaurtinib FLT3 inhibitory activity is modulated by concomitant azole therapy and may influence relapse risk [abstract]. Blood 2009; 114:326a.
49. Fabbro D, Ruetz S, Bodis S, et al. PKC412: a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000; 15:17-28. (Pubitemid 30364896)
50. Propper DJ, McDonald AC, Man A, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 2001; 19:1485-1492. (Pubitemid 32202557)
51. Stone RM, DeAngelo DJ, KlimekV, etal. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005; 105:54-60. (Pubitemid 40053063)
52. Fischer T, Stone RM, Deangelo DJ, et al. Phase IIB trial of oral midostaurin •• (PKC41 2), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk mye-lodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010; 28:4339-4345.
53. Stone RM, Fischer T, Paquette R, et al. Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML [abstract]. Blood 2005; 106:121a.
54. Escudier B, EisenT, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134. (Pubitemid 46089673)
55. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
56. Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005; 11:5472-5480. (Pubitemid 41060823)
57. Christiansen DH, Andersen MK, Desta F, Pedersen-Bjergaard J. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2005; 19:2232-2240. (Pubitemid 41741619)
58. Zhang W, KonoplevaM,Shi YX, etal. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008; 100:184-198. (Pubitemid 351480557)
59. Pratz KW, Cho E, Levis MJ, et al. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia 2010; 24:1437-1444.
60. Delmonte J Jr, Kantarjian H, Andreef M, et al. Update of a phase I study of sorafenib in patients with refractory/relapsed acute myeloid leukemia or high-risk myelodysplastic syndrome [abstract]. Blood 2007; 110:272a.
61. Safaian NN, Czibiere A, Bruns I, etal. Sorafenib (Nexavar) induces molecular remissions and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. Leuk Res 2009; 33:348-350.
62. Lee SH, Paietta E, Racevskis J, et al. Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation. Am J Hematol 2009; 84:701-702.
63. Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009; 113:6567-6571.
64. Ravandi F, Cortes JE, Jones D, etal. Phase I/II study of combination therapy •• with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010; 28:1856-1862.
65. Pratz KW, Sato T, Murphy KM, et al. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 2010; 115:1425-1432.
66. Griswold IJ,Shen LJ, LaRosee P, etal. Effects of MLN51 8, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood 2004; 104:2912-2918.
67. DeAngelo DJ, Stone RM, Heaney ML, et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 2006; 108:3674-3681. (Pubitemid 44864544)
68. Schittenhelm MM, Kampa KM, Yee KW, Heinrich MC. The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. Cell Cycle 2009; 8:2621-2630.
69. Cortes J, RobozGJ, Kantarjian H, etal. A phase I dose escalation study of KW-2449, an oral multi-kinase inhibitor against FLT3, Abl, FGFR1 and aurora in patients with relapsed/refractory AML, treatment resistant/intolerant CML, ALL and MDS [abstract]. Blood 2007; 110:277a.
70. Chao Q, Sprankle KG, Grotzfeld RM, et al. Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b] [1,3]ben zothiazol-2-yl]phenyl}ureadihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. J Med Chem 2009; 52:7808-7816.
71. Cortes J, Foran J, Ghirdaladze D, et al. AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human (FIH) phase 1 AML study [abstract]. Blood 2009; 114:636a.